Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-17 20:10 | 2026-06-15 | MRNA | Moderna, Inc. | Hoge Stephen | Officer | OPT+S | $51.37 | 53,336 | $2,739,870 | 1,483,848 |
| 2026-06-17 20:05 | 2026-06-15 | TWST | Twist Bioscience Corp | Green Paula | Officer | OPT+S | $81.67 | 26,137 | $2,134,489 | 120,705 |
| 2026-06-17 20:13 | 2026-06-15 | OCGN | Ocugen, Inc. | Johnson-Greene Treerita Essalima | Officer | BUY | $1.23 | 21,000 | $25,830 | 521,000 |
| 2026-06-18 00:11 | 2026-06-15 | ADPT | Adaptive Biotechnologies Corp | ROBINS HARLAN S | Officer | SELL | $17.41 | 106,160 | $1,847,938 | 1,405,898 |
| 2026-06-17 23:51 | 2025-06-16 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | Officer | OPT+S | $160.00 | 93,575 | $14,972,112 | 154,647 |
| 2026-06-17 22:24 | 2026-06-15 | COAG | Hemab Therapeutics Holdings, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% owner | BUY | $24.97 | 67,669 | $1,689,817 | 6,444,637 |
| 2026-06-17 21:25 | 2026-06-15 | PTHS | Pelthos Therapeutics Inc. | Friedberg Ezra M | Director | SELL | $27.29 | 283 | $7,724 | 81,600 |
| 2026-06-17 21:10 | 2026-06-15 | ABOS | Acumen Pharmaceuticals, Inc. | Porter Derrell | Director | OPT+S | $2.33 | 32,300 | $75,240 | 35,500 |
| 2026-06-17 20:17 | 2026-06-15 | TARS | Tarsus Pharmaceuticals, Inc. | LINK WILLIAM J PHD | Director | SELL | $62.12 | 12,500 | $776,495 | 106,786 |
| 2026-06-17 20:17 | 2026-06-15 | TARS | Tarsus Pharmaceuticals, Inc. | Goodrich Katherine | Director | SELL | $62.08 | 2,954 | $183,384 | 2,233 |
| 2026-06-17 20:17 | 2026-06-16 | TARS | Tarsus Pharmaceuticals, Inc. | Farrow Jeffrey S | Officer | OPT+S | $60.95 | 14,396 | $877,436 | 56,801 |
| 2026-06-16 22:08 | 2026-06-12 | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $8.66 | 531,326 | $4,599,902 | 16,763,043 |
| 2026-06-16 21:53 | 2026-06-15 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer | SELL | $125.40 | 3,000 | $376,200 | 171,646 |
| 2026-06-16 22:02 | 2026-06-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer | SELL | $123.92 | 3,000 | $371,762 | 124,234 |
| 2026-06-16 21:07 | 2026-06-15 | CGON | CG Oncology, Inc. | Mulay James | Director | OPT+S | $60.12 | 1,964 | $118,076 | 0 |
| 2026-06-16 20:30 | 2026-06-16 | AURA | Aura Biosciences, Inc. | Gibney Anthony S | Officer | SELL | $6.42 | 12,824 | $82,330 | 265,354 |
| 2026-06-16 20:03 | 2026-06-15 | IMVT | Immunovant, Inc. | Pande Atul | Director | OPT+S | $34.02 | 1,500 | $51,030 | 116,731 |
| 2026-06-15 20:05 | 2026-06-11 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | Officer | OPT+S | $148.01 | 10,000 | $1,480,139 | 158,222 |
| 2026-06-16 00:10 | 2026-06-11 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.96 | 7,685 | $45,773 | 2,652,574 |
| 2026-06-15 23:56 | 2026-06-12 | IPSC | Century Therapeutics, Inc. | Carr Douglas | Officer | SELL | $2.23 | 1,654 | $3,692 | 505,094 |
| 2026-06-15 23:57 | 2026-06-12 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | Officer | SELL | $2.23 | 2,584 | $5,767 | 512,319 |
| 2026-06-15 23:13 | 2026-06-11 | ADPT | Adaptive Biotechnologies Corp | BOBULSKY SUSAN | Officer | SELL | $19.00 | 5,000 | $95,000 | 411,775 |
| 2026-06-15 21:25 | 2026-06-11 | PTHS | Pelthos Therapeutics Inc. | Davis Todd C | Director | BUY | $27.82 | 35,948 | $999,983 | 75,834 |
| 2026-06-12 21:05 | 2026-06-10 | APGE | Apogee Therapeutics, Inc. | HENDERSON MICHAEL THOMAS | Director, Officer | SELL | $83.38 | 20,000 | $1,667,622 | 1,095,987 |
| 2026-06-11 20:05 | 2026-06-09 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.98 | 30,728 | $183,692 | 2,644,889 |
| 2026-06-11 23:36 | 2026-06-09 | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $7.44 | 1,027,722 | $7,650,157 | 16,231,717 |
| 2026-06-10 20:05 | 2026-06-08 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $69.84 | 402 | $28,077 | 119,692 |
| 2026-06-10 20:05 | 2026-06-08 | TWST | Twist Bioscience Corp | Green Paula | Officer | SELL | $69.84 | 884 | $61,742 | 120,705 |
| 2026-06-10 20:05 | 2026-06-08 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | SELL | $69.84 | 2,265 | $158,197 | 844,607 |
| 2026-06-10 20:05 | 2026-06-08 | TWST | Twist Bioscience Corp | WERNER ROBERT F. | Officer | SELL | $69.20 | 1,359 | $94,046 | 46,827 |
| 2026-06-10 20:51 | 2026-06-09 | ABOS | Acumen Pharmaceuticals, Inc. | Fountain Nathan B | Director | SELL | $2.23 | 6,400 | $14,273 | 48,150 |
| 2026-06-10 15:19 | 2026-06-05 | MGX | Metagenomi Therapeutics, Inc. | Wein Matthew | Officer | SELL | $1.30 | 558 | $725 | 126,491 |
| 2026-06-10 15:21 | 2026-06-05 | MGX | Metagenomi Therapeutics, Inc. | Irish Jian | Director, Officer | SELL | $1.30 | 3,737 | $4,854 | 377,533 |
| 2026-06-10 15:23 | 2026-06-05 | MGX | Metagenomi Therapeutics, Inc. | Wapnick Pamela | Officer | SELL | $1.30 | 2,884 | $3,746 | 208,491 |
| 2026-06-09 20:10 | 2026-06-08 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | Officer | SELL | $2.11 | 524 | $1,106 | 514,903 |
| 2026-06-09 20:10 | 2026-06-08 | IPSC | Century Therapeutics, Inc. | Carr Douglas | Officer | SELL | $2.11 | 249 | $526 | 506,748 |
| 2026-06-09 20:05 | 2026-06-05 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.83 | 10,054 | $58,596 | 2,614,161 |
| 2026-06-09 21:37 | 2026-06-09 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer | BUY | $0.85 | 5,000 | $4,250 | 298,266 |
| 2026-06-09 21:40 | 2026-06-05 | NBIX | NEUROCRINE BIOSCIENCES INC | SHERWIN STEPHEN A | Director | OPT+S | $165.32 | 25,000 | $4,132,970 | 15,860 |
| 2026-06-09 00:27 | 2026-06-04 | ADPT | Adaptive Biotechnologies Corp | BOBULSKY SUSAN | Officer | SELL | $18.00 | 11,000 | $198,000 | 416,775 |
| 2026-06-09 00:29 | 2026-06-04 | ADPT | Adaptive Biotechnologies Corp | LO FRANCIS | Officer | OPT+S | $17.49 | 39,741 | $695,070 | 250,934 |
| 2026-06-08 22:07 | 2026-06-04 | NBIX | NEUROCRINE BIOSCIENCES INC | Norwalk Leslie V | Director | SELL | $168.06 | 1,250 | $210,072 | 2,838 |
| 2026-06-08 20:34 | 2026-06-04 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | Officer | OPT+S | $50.00 | 3,471 | $173,550 | 67,468 |
| 2026-06-05 20:30 | 2026-06-04 | CGON | CG Oncology, Inc. | POST LEONARD E | Director | OPT+S | $54.50 | 1,000 | $54,500 | 0 |
| 2026-06-06 00:00 | 2026-06-03 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Officer | OPT+S | $78.71 | 5,500 | $432,905 | 205,648 |
| 2026-06-05 22:38 | 2026-06-04 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Director, Officer, 10% owner | SELL | $308.12 | 25,000 | $7,702,985 | 1,450,253 |
| 2026-06-05 22:40 | 2026-06-04 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Director, Officer, 10% owner | SELL | $308.11 | 25,000 | $7,702,825 | 1,378,155 |
| 2026-06-05 21:56 | 2026-06-04 | KOD | Kodiak Sciences Inc. | BORGESON JOHN A. | Officer | OPT+S | $34.10 | 30,000 | $1,023,009 | 211,930 |
| 2026-06-05 22:04 | 2026-06-04 | INKT | MiNK Therapeutics, Inc. | Ryan Barbara | Director | SELL | $12.76 | 1,500 | $19,141 | 21,969 |
| 2026-06-05 21:29 | 2026-06-04 | IBRX | ImmunityBio, Inc. | Simon Barry J. | Director | SELL | $7.18 | 23,033 | $165,306 | 2,827,788 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.